ARALAST Safety

ARALAST AATmosphere

Call on our team of personal advocates to support Alphas and their families at ARALAST AATmosphere.

Alpha1Health.com Survey

Take our survey to help us best meet the needs of the Alpha-1 community.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is prepared from human plasma using the Cohn-Oncley cold alcohol fractionation process.

ARALAST has a multi-step purification process that includes two viral treatment steps:

Solvent Detergent Treatment rapidly inactivates lipid-enveloped viruses such as HIV and Hepatitis B and C.
Nanofiltration reduces the risk of transmission of non-lipid-enveloped viral agents such as Hepatitis A and Parvovirus B19.

As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information

To view PDF, you will need Adobe® Acrobat® Reader® software.